The Tel Aviv Stock Exchange (TASE) fell today. The Tel Aviv 25 Index fell 1.69% to 1,090.20 points, the Tel Aviv 100 Index fell 1.72% to 989.01 points, and the BlueTech 50 Index fell 2.22% to 274.93 points. Turnover was NIS 1.13 billion.
The TASE reversed yesterday's gains, in line with today's losses on Asian and European markets, and losses at the opening on Wall Street, amid new worries about the Eurozone. S&P threatened to downgrade Eurozone economies, include AAA-rated France and Germany.
In the bond market, both long-term Shahar shekel bonds were unchanged and long-term Galil CPI-linked bonds rose by up to 0.2%. The corporate bond benchmark Tel-Bond 20 Index rose 0.50%.
In the foreign currency market, the Bank of Israel set the shekel-dollar representative exchange rate at $3.736/$, up 0.24% on yesterday's rate, and set the shekel-euro representative exchange rate at NIS 5.009/€, down by less than 0.01%.
In the stock market, Gazit-Globe Ltd. (TASE: GLOB) fell 5.2%, for the biggest lost among Tel Aviv 25 shares, after filing its prospectus for an offering on the New York Stock Exchange.
The banks, which led yesterday's gains, helped pull the market down today. Bank Leumi (TASE: LUMI) fell 3.3% and Bank Hapoalim (TASE: POLI) fell 2.3%. The Banking Index fell 2.9%.
Israel Corporation (TASE: ILCO) fell 4%, and subsidiary Israel Chemicals Ltd. (TASE: ICL) fell 2.8%.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) was the only Tel Aviv 25 share to buck the market, and just barely, with a gain of 0.1%, after joining the Nasdaq 100 Index today, and its index peer, Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) fell 0.1% on the day's biggest turnover of NIS 60 million.
Also in the life sciences, Tel Aviv 100 Protalix Biotherapeutics Inc. (AMEX:PLX; TASE: PLX) fell 18.5%, after the US Food and Drug Administration (FDA) postponed approval of the company's treatment for Gaucher's disease by three months, and BiolineRX Ltd. (TASE:BLRX; Nasdaq; BLRX) rose 6.6% after reporting success in a Phase I clinical trial.
Tefen Operations Management Consulting Ltd. (TASE: TEFN) rose 4.5% after signing a strategic cooperation agreement with Chinese business consultancy firm Allpku Ltd.
Published by Globes [online], Israel business news - www.globes-online.com - on December 6, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011